Novartis to Discontinue CIRRUS-1 Study of CFZ533 (iscalimab) in Kidney Transplant Patients

 Novartis to Discontinue CIRRUS-1 Study of CFZ533 (iscalimab) in Kidney Transplant Patients

Novartis’s Adakveo (crizanlizumab) Receives NICE Recommendation as a New Therapy for Sickle Cell Disease

Shots:

  • The discontinuation is based on the interim analysis of data from the CIRRUS-1 study demonstrating that CFZ533 (iscalimab)-based treatment is less efficacious compared to tacrolimus-based treatment in the prevention of organ rejection in patients receiving a kidney transplant
  • In the study, both CFZ533 and tacrolimus were used in combination with other immunosuppressive therapies (induction therapy, mycophenolate and corticosteroids)
  • The company will continue the study of CFZ533 in liver transplant as the studies are exploring the potential treatment in other conditions, such as hidradenitis suppurativa and Sjögren’s syndrome

Click here to­ read full press release/ article | Ref: Novartis | Image: BioProcess International

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post